Objective To investigate the clinical effect of Erlotinib in the treatment of advanced non-small cell lung cancer.Methods A total of 176 patients with advanced non-small cell lung cancer admitted to the Zhongyi Northeast International Hospital from January 2017 to June 2019 were selected as the research objects.According to the random number table method, they were divided into the control group (88 cases) and the experimental group (88 cases).The control group was treated with Docetaxel, and the experimental group was treated with Erlotinib.The 1-year survival,adverse reactions and disease remission of the two groups were compared.Results During the follow-up period of 1 year, the disease progression free survival duration of the experimental group was longer than that of the control group, the quality of life score of the experimental group was higher than that of the control group, the differences were statistically significant (P＜0.05); the total incidence rate of adverse reactions in the experimental group was lower than that in the control group, the difference was statistically significant (P＜0.05); the disease remission rate of the experimental group was higher than that of the control group, the difference was statistically significant (P＜0.05).Conclusion Erlotinib has significant clinical effect in the treatment of advanced non-small cell lung cancer, with good 1-year survival, low incidence of adverse reactions and high disease remission rate.It is recommended that this option be preferred in clinical treatment.